Miracell to Participate in KIMES 2022 with Advanced Stem Cell Medical Devices
Miracell to Participate in KIMES 2022 with Advanced Stem Cell Medical Devices Extraction of large quantities of stem cells through centrifugation with minimal manipulation Miracell announced on the 6th that it plans to participate in the medical device exhibition “KIMES 2022.” The 37th Korea International Medical & Hospital Equipment Show (KIMES 2022) will be held for four days from the 10th to the 13th,under the theme “KIMES, Where New Hope Begins.” Miracell’s “Smart M-cell 2” is a cutting-edge regenerative medical bio-device that extracts large quantities of stem cells through centrifugation with minimal manipulation,enriched and automatically separated. The company explained that the device, a “bone marrow and blood stem cell extraction device including a centrifuge vessel capable of selective separation,”has received approval from the Ministry of Food and Drug Safety and certification as a new medical technology by the Ministry of Health and Welfare. Stem cells have recently been recognized for their limitless benefits in cartilage defects, pain management, preventive medicine, and holistic healthcare, attracting increasing interest from medical professionals and industry professionals. Miracell’s Cellpia Global Platform (CGP) shares stem cell medical technology through a network of member hospitals and clinics. CGP provides education, technology transfer, medical equipment setup, and marketing to hospitals in Korea and abroad to ensure safer stem cell regenerative medicine treatments. A company representative explained, “Miracell’s CGP hospitals are located in major cities across the country, including Daejeon, Daegu, Gwangju, Ulsan, and Busan, in addition to the Seoul metropolitan area, offering orthopedic, plastic, dermatological, urological, obstetrics and gynecological, and family medicine services.” By Sangjun Ahn ansang@viva100.com
Miracell’s ‘Smart Mcell 2’ Targets the Middle East: Massive Stem Cell Extraction After Blood Concentration
Miracell’s “Smart M-Cell 2” Targets the Middle East: Massive Stem Cell Extraction After Blood Concentration Received Ministry of Health and Welfare “New Health Technology” certificationPerformance demonstrated at Seoul National University Bundang HospitalPraise received at Dubai Medical Equipment Exhibition Miracell, a stem cell specialist, is aggressively targeting the Middle Eastern market following its European expansion. Shin Hyun-soon, CEO of Miracell, recently met with Maeil Business Newspaper at the Miracell headquarters in Yeoksam-dong, Seoul.“Miracell’s cutting-edge bio-stem cell extraction system is receiving enthusiastic responses in the Middle East, including the United Arab Emirates (UAE),” he said. “These afternoons are filled with Zoom meetings with Middle Eastern countries.” Founded in 2009, Miracell’s core businesses include cell storage services, medical device and cosmetic manufacturing, and stem cell therapy. Stem cells are so small that they cannot be used immediately after extraction,needing separation and concentration. Miracell developed its own stem cell extraction device, which received “New Health Technology” certification from the Ministry of Health and Welfare in February of last year. The company’s “Smart M-cell 2” is a regenerative medical device that extracts bone marrow and blood, concentrates them through centrifugation, and then automatically extracts a large amount of isolated stem cells. Approximately 2.9 billion cells can be extracted per session in less than an hour. Equipped with a special LED to enhance cell activity,it is currently being used for therapeutic purposes at major hospitals in Korea. CEO Shin stated, “Smart M-cell 2 has shown clinical trials at the Seoul Institute of Medical Science and Bundang Seoul National University Hospitalto outperform Harvard Medical School’s Immunology Research Institute’s “Smart Prep” in terms of cell viability and recovery rates. Expectations are high.” He added, “Having received an enthusiastic response at the Dubai International Medical Device Exhibition earlier this year,we will actively pursue our global market expansion, including in the Middle East.” CEO Shin is also developing an app to popularize stem cell treatment. CEO Shin explained, “We will create a global platform that connects domestic and international patients with hospitals around the world, making it easier for patients around the world to exchange treatment information.” Reporter Yoo Joo-yeon